Alfacell Finishes Six-Year Mesothelioma Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm opens Phase IIIb database on would-be competitor to Lilly’s Alimta.
You may also be interested in...
Alfacell Plans Subset Onconase NDA Despite Phase III Shortfall In Mesothelioma
Drug works in chemo failures; filing by year’s end, CFO tells “The Pink Sheet” DAILY.
Alfacell Plans Subset Onconase NDA Despite Phase III Shortfall In Mesothelioma
Drug works in chemo failures; filing by year’s end, CFO tells “The Pink Sheet” DAILY.
Lilly Alimta To Be Available In Two Weeks Following Five-Month Review
Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.